Clinical Trial Update: Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and dosage of combining irinotecan and temozolomide in patients with recurrent primary malignant glioma has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Brain Neoplasms
• Central Nervous System Neoplasms
• Glioma

Drugs mentioned

• Camptosar (irinotecan)
• Temodar (Temozolomide)

Snippet

Sponsor: Duke University | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED